What is GlucoTrack?
GlucoTrack, Inc. operates as a specialized medical device developer dedicated to the design and commercialization of novel technologies for individuals managing diabetes and pre-diabetic conditions. The company's flagship product, the GlucoTrack device, represents a significant advancement in diagnostic accessibility, enabling users to obtain accurate blood glucose readings without the physical discomfort associated with conventional testing. Based in New Jersey, the firm leverages proprietary engineering to address the critical need for seamless, continuous health monitoring in the United States market. By integrating sophisticated sensor technology with user-friendly interfaces, GlucoTrack is effectively disrupting the standard of care for chronic disease management.
How much funding has GlucoTrack raised?
GlucoTrack has raised a total of $25.6M across 2 funding rounds:
Other Financing Round
$100K
Private Equity
$20M
Other Financing Round (2024): $100K, investors not publicly disclosed
Private Equity (2025): $20M led by Sixth Borough Capital Management
Key Investors in GlucoTrack
Sixth Borough Capital Management
Sixth Borough Capital Management is a multi-stage, event-driven alternative investment manager that focuses on small and mid-cap private and public equities, with a strong interest in healthcare and technology innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GlucoTrack?
With the recent influx of capital, GlucoTrack is poised to accelerate its commercialization efforts and expand its operational footprint. The strategic backing from institutional investors provides the necessary runway to scale manufacturing capabilities and enhance research and development initiatives. Future growth will likely focus on clinical validation and market penetration, as the company seeks to solidify its presence within the competitive landscape of digital health and medical diagnostics. As the firm transitions into this next phase of enterprise-level growth, the focus remains on scaling its noninvasive platform to improve patient outcomes and operational efficiency across the healthcare ecosystem.
See full GlucoTrack company page
